G. K. Schwartz, et al., J. Natl. Cancer Inst., vol. 87, No. 18, 1995, pp. 1394-1399. |
Uhlmann E, et al. "Antisense oligonucleotides: A new therapeutic principle." Chem. Rev. 90: 543-584, 1990. |
Skorski T, et al. "Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligonucleotides combined with mafosfamide." J. Clin. Invest. 92: 194-202, 1993. |
Malgorzata N-S. "Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: A new approach for tumor treatment." Folia Histochemica et Cytobiologica 32: 35-40, 1994. |
Monia BP. "Evaluation of 2' modified oligonucleotides containing 2-deoxy gaps as antisense inhibitors of gene expression." JBC 268: 14514-14522, 1993. |
Nishizuka Y. "The molecular heterogeneity of protein kinase C and its implications for cellular regulation." Nature 334: 661-665, 1988. |
Orkin SH. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.", 1995. |
Szczylik et al "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides" Science vol. 253 (1991) pp. 562-565. |
Nieborowska-Skorska| "Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: A new approach for tumor treatment ?." Folia Histochemica et Cytobiologica, vol. 32, No. 1, 1994 pp. 35-40. |
Taroszewski et al "Concerning Antisense Inhibition of the Multiple Drug Resistance Gene" Cancer Communications, vol. 2, No. 8 1990 (pp. 287-294). |
Isis Pharmaceuticals Press Release dated Jan. 23, 1996, "Isis Pharmaceuticals Initiates Clinical trials with Novel Antisense Cancer Compound Targeted to PKC-a Inhibition". |
Calabretta "Inhibition of Protooncogene Expression by Antisense Oligodeoxynucleotides: Biological and Therapeutic Implications" Cancer Research 54, 4505-4510 Sep. 1991. |
Skorski et al "Highly Efficient Elimination of Philadelphia Leukemic Cells by Exposure to bcr/abl Antisense Oligodeoxynucleotides Combined with Mafosfamide" J Clinical Invest vol. 92, (1993) 194-202. |
Corrias "An Oligomer Complimontary to the 5' End Region of MDRL Gene Decreases Resistance to Doxorubicin of Human Adenocarcinoma-Resistance Cells" Anticancer Research 12, 1431-1438 (1992). |
Derwent Abstract 96-354302 �35!, 1996. |
Chemical Abstract, vol. 37, No. 2807, 511, 1996. |
Guleria et al, Nature Medicine 2 (3), 334 (1996). |
Mizutani et al, Cancer 74 (9), 2546 (1994). |
Milligan et al, J. Med. Chem 36 (14), 1923 (1993). |
Clark et al, Cancer Supplement 78 (3), 688 (1996). |
Chemical Abstract, vol. 37, No. 240.5, 352, 1996. |
Ma et al, Fundam Clin. Pharmacol. 10, 97-115 (1996). |
Citti et al, Carcinogenesis 17 (1), 25-29 (1996). |
Chemical Abstract, vol. 86, No. 2955, 1, 742a, (1995). |
Chemical Abstract, vol. 36, No. 2571, 431 (1995). |
Chemical Abstract, vol. 36, No. 2032, 341, (1996). |
Chemical Abstract, vol. 36, No. 1704, 287, (1996). |
Steele et al, Cancer Research 53, 2330 (1993). |
Chemical Abstract, vol. 153, No. 166, 270A, (1995). |
Chemical Abstract, vol. 84, No. 2043, 1,514a (1994). |
Chemical Abstract, vol. 35, No. 1543, 258, (1994). |
Chemical Abstract, vol. 84, No. 552, (1994). |
Tortora et al, Biochem. Biophys. Res. Commun. 177 (3), 1133 (1991). |
Chemical Abstract, vol. 32, No. 2570, (1991). |
Chemical Abstract, vol. 31, No. 221, (1990). |
Alama et al., Pharm Res. 22, Suppl. 2,2 (1990). |
Dean et al, J. Biol. Chem. 269 (23), 16416-24(1994). |
Maier, et al, Experimental Cell Research 205, 52-58 (1993). |
The Genesis Report/Rx, Jun. 1993, p. 15. |
Ahmad et al, Mol. Pharmacology 43, 858 (1993). |
Chemical Abstract, vol. 33, No. 550, 92, (1992). |
Chemical Abstract, vol. 57, (2), 1005-B (1996). |
Cho-Chung et al, Pharm. Ther. 60, 265-88 (1993). |
Roninson: Cancer Biotechnology Weekly Nov. 6, 1995. |
Blagosklonny et al, Cancer Researcher Weekly Sep. 26, 1994. |
Cho-Chung: Crisp data Base NIH, Publication year 1994 (entered into database Jul. 1995). |
Chemical Abstract, vol. 95, 206843, (1994). |
Blagosklonny et al, Anti-Cancer Drugs 5, 437-442 (1994). |
Baltuch et al, J. Neuro-Oncology 24, 241-50 (1995). |
Proc. Amer. Assoc. Cancer Res. vol. 35, p. 617, No. 3680 (1994). |